DDInter1570 DDInter810
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Gefitinib
Ranolazine {u} (Compound) upregulates {v} (Gene) WDR7
WDR7 {u} (Gene) is upregulated by {v} (Compound) Gefitinib
Ranolazine {u} (Compound) downregulates {v} (Gene) MRPS16
MRPS16 {u} (Gene) is downregulated by {v} (Compound) Gefitinib
Ranolazine {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Gefitinib
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Iloperidone
Iloperidone {u} (Compound) resembles {v} (Compound) Gefitinib
Ranolazine {u} (Compound) upregulates {v} (Gene) WDR7
WDR7 {u} (Gene) is upregulated by {v} (Compound) Erlotinib
Erlotinib {u} (Compound) resembles {v} (Compound) Gefitinib
Ranolazine {u} (Compound) downregulates {v} (Gene) MRPS16
MRPS16 {u} (Gene) is downregulated by {v} (Compound) Afatinib
Afatinib {u} (Compound) resembles {v} (Compound) Gefitinib
Ranolazine {u} (Compound) downregulates {v} (Gene) ATP6V1D
ATP6V1D {u} (Gene) is regulated by {v} (Gene) CSNK1E
CSNK1E {u} (Gene) is bound by {v} (Compound) Gefitinib
Ranolazine {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Iloperidone
Iloperidone {u} (Compound) resembles {v} (Compound) Gefitinib
Ranolazine {u} (Compound) causes {v} (Side Effect) Pancreatitis
Pancreatitis {u} (Side Effect) is caused by {v} (Compound) Erlotinib
Erlotinib {u} (Compound) resembles {v} (Compound) Gefitinib
Ranolazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Gefitinib (Compound)
Ranolazine (Compound) upregulates WDR7 (Gene) and WDR7 (Gene) is upregulated by Gefitinib (Compound)
Ranolazine (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is downregulated by Gefitinib (Compound)
Ranolazine (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Gefitinib (Compound)
Ranolazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Iloperidone (Compound) and Iloperidone (Compound) resembles Gefitinib (Compound)
Ranolazine (Compound) upregulates WDR7 (Gene) and WDR7 (Gene) is upregulated by Erlotinib (Compound) and Erlotinib (Compound) resembles Gefitinib (Compound)
Ranolazine (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is downregulated by Afatinib (Compound) and Afatinib (Compound) resembles Gefitinib (Compound)
Ranolazine (Compound) downregulates ATP6V1D (Gene) and ATP6V1D (Gene) is regulated by CSNK1E (Gene) and CSNK1E (Gene) is bound by Gefitinib (Compound)
Ranolazine (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Iloperidone (Compound) and Iloperidone (Compound) resembles Gefitinib (Compound)
Ranolazine (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Erlotinib (Compound) and Erlotinib (Compound) resembles Gefitinib (Compound)